Lexicon Pharmaceuticals
LXRX
132 hedge funds and large institutions have $1.32B invested in Lexicon Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 52 increasing their positions, 31 reducing their positions, and 10 closing their positions.
162% more call options, than puts
Call options by funds: $8.78M | Put options by funds: $3.35M
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
68% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 31
12% more funds holding
Funds holding: 118 → 132 (+14)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less capital invested
Capital invested by funds: $1.46B → $1.32B (-$137M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$9.09M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$6.71M |
| 3 |
FPC
Falcon Point Capital
San Francisco,
California
|
+$2.72M |
| 4 |
Millennium Management
New York
|
+$2.4M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$2.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$12.9M |
| 2 |
BM
Bridger Management
New York
|
-$4.34M |
| 3 |
KCM
Kingdon Capital Management
New York
|
-$2.62M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2M |
| 5 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
-$1.89M |
LXRX Hedge Fund Activity: Q1 2016 in Review
132 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q1 2016, worth a combined $1.32B — down 9.3% from $1.46B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new LXRX positions and 10 closed out — a net gain of 15 holders — while 52 added to existing stakes and 31 trimmed.
The largest buyer was Eagle Asset Management, adding an estimated $9.09M. The largest seller was UBS AM, cutting an estimated $12.9M.
- 132 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q1 2016, up from 118 in Q4 2015.
- Funds reported $1.32B of Lexicon Pharmaceuticals stock for Q1 2016, down 9.3% quarter-over-quarter.
- 25 funds opened new Lexicon Pharmaceuticals positions in Q1 2016 and 10 closed out, a net change of +15 holders.
- The largest Lexicon Pharmaceuticals buyer in Q1 2016 was Eagle Asset Management, an estimated $9.09M added.
- The largest Lexicon Pharmaceuticals seller in Q1 2016 was UBS AM, an estimated $12.9M sold.
Based on aggregated 13F filings for Q1 2016.